dgn-np:NP13919.RAEjrGZVvDx4-uCJDjhqRnflQO08s09u1xj9TcNeAQPcI130_provenance {
  dgn-np:NP13919.RAEjrGZVvDx4-uCJDjhqRnflQO08s09u1xj9TcNeAQPcI130_assertion dcterms:description "[However, it is very difficult to find patients that are applicable for this therapy, because: (1) only 5-13% of DMD patients have nonsense mutations in the dystrophin gene, (2) it is challenging to find nonsense mutations in the gene because dystrophin cDNA is very long (14 kb), and (3) the efficiency of aminoglycoside-induced read-through is dependent on the kind of nonsense mutation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ;
    wi:evidence dgn-void:source_evidence_curated ;
    sio:SIO_000772 miriam-pubmed:16122626 ;
    prov:wasDerivedFrom dgn-void:ctd_human-20130708 ;
    prov:wasGeneratedBy eco:ECO_0000218 .
  dgn-void:ctd_human-20130708 pav:importedOn "2013-07-24"^^xsd:date .
  dgn-void:source_evidence_curated a eco:ECO_0000205 ;
    rdfs:comment "Gene-disease associations manually curated."@en ;
    rdfs:label "DisGeNET evidence - CURATED"@en .
}